Significant global cardiovascular risk linked to high lipoprotein(a) levels

Review in The Lancet finds that one in five globally are at risk of contracting cardiovascular diseases, because they carry a genetic risk of high levels of a specific lipoprotein, which can be tested for and possibly treated.

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.

March 11, 2024

Bayer and MOMA Therapeutics partner for oncology programme

Bayer will oversee the programme’s progression through further preclinical development and potential commercialisation. Credit: Lightspring/Shutterstock. Bayer has entered a strategic collaboration with MOMA Therapeutics to

October 8, 2024

WHO recommends a comprehensive set of tobacco cessation interventions

The World Health Organization (WHO) recommends a comprehensive set of tobacco cessation interventions, including behavioral support delivered by health-care providers, digital cessation interventions and pharmacological

July 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.